Drug Profile
AZD 5745
Alternative Names: AZD5745Latest Information Update: 10 Aug 2005
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Gastrokinetics
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastro-oesophageal reflux
Most Recent Events
- 28 Jul 2005 Discontinued - Preclinical for Gastro-oesophageal reflux in Europe (unspecified route)
- 20 Oct 2004 Preclinical trials in Gastro-oesophageal reflux in Europe (unspecified route)